Fig. 2
From: Do we still need breast cancer screening in the era of targeted therapies and precision medicine?
Effect of screening and chemotherapy on breast cancer recurrences among women aged 60 to 74 years, diagnosed with breast cancer between 1992 and 1999. Stage distribution was derived from Puliti et al. [21] considering attenders and non-attenders to screening mammography; 5% overdiagnosis attributed to screening mammography is taken into account. HR+ and HR− recurrences are back-calculated from Mariotto et al. [24]. The worst scenario reflects the absence of mammography screening and the use of chemotherapy alone. BCs, breast cancers; HR+, hormone receptor-positive breast cancers; HR−, hormone receptor-negative breast cancers